Russia’s COVID-19 vaccine Sputnik V will be produced in India by generic pharmaceutical firm Hetero.
Announcing an agreement with Hetero, sovereign wealth fund RDIF — which is piloting the vaccine — said more than 100 million doses of the vaccine would be produced.
A joint statement from the Russian Direct Investment Fund (RDIF) and Hetero on Friday said the agreement was to produce more than 100 million doses per year in India. The production is intended to start at the beginning of 2021. Hetero would manufacture the vaccine through its subsidiary Hetero Biopharma, which has a facility in Hyderabad. It will be equipped with sufficient capacity, sources said.
RDIF’s CEO Kirill Dmitriev said the agreement would pave the way for production of the ‘safe and highly effective’ Sputnik V vaccine on Indian soil. The vaccine’s interim clinical trial results show 95% efficacy on the 42nd day after the first dose.
“We are pleased to collaborate with RDIF as a manufacturing partner for Sputnik V vaccine for the treatment of COVID-19,” said Hetero Labs director-International Marketing B. Murali Krishna Reddy.
“While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients,” he added.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
Please Email the Editor